Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

NCT02113007 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Closed early due to slow accrual.

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Rituximab plus Temozolomide

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]